Arcutis Biotherapeutics
Price & Volume
Stats
See more52W Range | $2.96-$15.79 |
Market Cap | $1.7B |
Shares Short | 23M |
Financials
See moreRevenue (12 Mos) | $138.7M |
Revenue Growth (YoY) | 17.4% |
Gross Profit (12 Mos) | $2.9M |
Diluted EPS | -$1.67 |
News
See moreYahoo Finance • last year
UPDATE 1-US FDA approves Arcutis' drug to treat chronic skin disease
Yahoo Finance • last year
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
Yahoo Finance • last year
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
Yahoo Finance • last year
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript
About
CEO | Mr. Todd Franklin Watanabe M.A. |
Address | 3027 Townsgate Road, Westlake Village, CA, United States, 91361 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 296 |
